A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26- Year-Old Men and 16- to 26- Year-Old Women

Investigator: Joel Palefsky, MD
Sponsor: Merck and Co., Inc.

Location(s): South Africa; Malaysia; Thailand; Israel; Turkey; Denmark; Germany; Norway; Poland; Spain; Sweden; Mexico; Colombia; Peru; Canada


The overall goal is to bridge V503 efficacy findings in young women to young men based on the demonstration of similar immunogenicity and safety profiles. Study participants will be administered a 3-dose regimen of V503. They will be assessed for immunogenicity 1 month following completion of vaccination. All participants will be followed for safety for a total of 12 months.